IP Group

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Founded in Philadelphia in 2018, Innervace is a regenerative therapy company focused on developing implantable tissue-engineered brain pathways for neurodegenerative disorders. Its lead product is a tissue-engineered nigrostriatal pathway designed to mimic the lost pathway in Parkinson's patients, providing potential disease-modifying therapies.

Abliva AB is a Swedish pharmaceutical company focused on the research and development of treatments for primary mitochondrial diseases, which are rare and severe conditions caused by dysfunctional mitochondria. The company's pipeline includes KL1333, currently in phase I clinical trials, and NV354, an energy replacement therapy that is preparing for clinical trials. KL1333 is noted for its role as a regulator of NAD+ and NADH, and has received orphan drug designation in both Europe and the United States. Additionally, Abliva is developing NeuroSTAT for the treatment of traumatic brain injury. Established in 2000 and headquartered in Lund, Sweden, Abliva has formed collaborations with various institutions, enhancing its research capabilities and clinical development efforts.

MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Oxular is a clinical-stage company developing innovative retinal therapeutics. It focuses on transforming the treatment of retinal diseases by offering tissue-specific drug delivery solutions to address unmet patient needs, such as age-related macular degeneration and diabetic macular edema.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Centessa Pharmaceuticals is a biopharmaceutical company that focuses on advancing validated drug programs through an asset-centric R&D model. Each program is developed by dedicated subsidiaries, supported by centralized infrastructure and expert management.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

MOBILion Systems designs and commercializes SLIM-based ion mobility technology that enables lossless ion transfer and manipulation for separating and detecting biomolecules that are challenging to distinguish with conventional instruments. The company's systems provide high sensitivity, resolution, and throughput to analyze proteins, peptides, metabolites, glycans, and lipids, supporting biomarker discovery, early disease detection, and accelerated biologics development. By enabling rapid analysis of population-scale samples, the technology aims to improve diagnostics, monitor treatment, and advance precision medicine.

Founded in 2017, Kira Biotech is an Australian biotechnology company dedicated to developing novel immunomodulatory compounds. Its lead candidate, KB312, is a first-in-class monoclonal antibody targeting activated immune cells to induce immune tolerance and treat immune system disorders such as rheumatoid arthritis and systemic lupus erythematosus.

CareAlign is a developer of a real-time data system that enhances the management and coordination of clinical care for clinicians. The company offers an intuitive, patient-centric task management tool that allows healthcare professionals to assign tasks, set deadlines, and categorize them based on urgency. By aggregating data from multiple sources, CareAlign provides a comprehensive and clinically intuitive display of patients' clinical status, facilitating better understanding and decision-making in patient care. This system aims to streamline workflows and improve communication among clinicians, ultimately enhancing the quality of care delivered to patients.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Istesso is a biotechnology company focused on drug discovery and development in the field of immunometabolism. Founded in 2017, the company aims to create disease-resolving therapies for chronic autoimmune and inflammatory conditions, including rheumatoid arthritis and multiple sclerosis. Istesso's pipeline consists of both pre-clinical and clinical assets that work by reprogramming metabolic processes to address these complex diseases. By specializing in immune metabolism, Istesso is dedicated to providing innovative solutions that enhance the diagnosis and treatment of serious health conditions, ultimately aiming to improve patient outcomes.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Lorem Therapeutics is focusing on development early stage therapeutics in the phase between initial drug discovery and when a treatment begins review by the FDA for status as an Investigational New Drug. The company will use the funding “to accelerate and enhance our drug discovery efforts around critical cancer indications,” Slusher said in a statement.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, that specializes in non-contact vital signs monitoring. Founded in 2012, it has developed the Oxecam software, which allows for the remote measurement of heart rate, respiratory rate, and blood oxygenation using digital video cameras. This innovative approach is particularly beneficial in medical settings, where it can enhance care for elderly and vulnerable individuals in environments where staff presence is limited. The system generates alerts for risky activities and provides objective data on patient vitals, enabling informed care planning. Oxehealth's technology combines proprietary algorithms that leverage deep learning, computer vision, and signal processing, making it suitable for various sectors, including healthcare, security, and retail. Its Digital Care Assistant supports clinicians and caregivers in mental health facilities, prisons, and home care, facilitating proactive interventions based on real-time data. Oxehealth is recognized for achieving the world’s first medical device certification for its software, demonstrating its commitment to enhancing patient care through innovative technology.

Zilico develops medical diagnostic devices using electrical impedance spectroscopy technology. Its primary product, ZedScan, enhances cervical cancer diagnosis by providing real-time, objective assessments alongside colposcopy.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Relitect Limited is a technology company based in Motherwell, United Kingdom, focused on developing innovative diagnostic solutions for the life sciences industry. Founded in 2014, Relitect specializes in a novel assay platform that enables label-free electrochemical detection of binding events. This proprietary technology allows for the highly sensitive analysis of proteins, small molecules, and nucleic acids, making it suitable for clinical diagnostics and research applications. By utilizing small sample volumes and a multiplexed format, Relitect's technology minimizes sample interference and eliminates the potential for cross-talk between labeled reagents, enhancing the accuracy of biomarker detection.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that specializes in developing hormone therapeutics for the treatment of chronic endocrine conditions. Founded in 2004, the company aims to provide innovative solutions for conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal's notable products include Alkindi, a replacement therapy for pediatric adrenal insufficiency, and Chronocort, which has completed Phase III clinical trials for adrenal insufficiency and congenital adrenal hyperplasia. The company is also advancing its early-stage pipeline with products such as Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release preparation of T3 hormone for hypothyroidism. Diurnal's research emphasizes circadian-based endocrinology, focusing on physiological treatment regimes to address the needs of patients with rare and chronic endocrine disorders.

Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, that specializes in non-contact vital signs monitoring. Founded in 2012, it has developed the Oxecam software, which allows for the remote measurement of heart rate, respiratory rate, and blood oxygenation using digital video cameras. This innovative approach is particularly beneficial in medical settings, where it can enhance care for elderly and vulnerable individuals in environments where staff presence is limited. The system generates alerts for risky activities and provides objective data on patient vitals, enabling informed care planning. Oxehealth's technology combines proprietary algorithms that leverage deep learning, computer vision, and signal processing, making it suitable for various sectors, including healthcare, security, and retail. Its Digital Care Assistant supports clinicians and caregivers in mental health facilities, prisons, and home care, facilitating proactive interventions based on real-time data. Oxehealth is recognized for achieving the world’s first medical device certification for its software, demonstrating its commitment to enhancing patient care through innovative technology.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Exonate is a biotechnology company focused on developing small molecule drugs that modulate alternative messenger RNA splicing. It specializes in ophthalmology, with a primary focus on treating diabetic retinopathy and diabetic macular oedema (DMO), as well as wet age-related macular degeneration (wAMD). The company's lead program aims to provide superior efficacy through topical agents in preclinical models of wAMD.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, focusing on the ubiquitin and ubiquitin-like signaling systems. The company provides protein degradation-focused drug discovery services and designs novel deubiquitylase (DUB) enzyme inhibitors as potential therapeutics for addressing unmet medical needs. Ubiquigent collaborates with both academic and pharmaceutical researchers, supporting fundamental scientific discovery and the exploration of innovative drug candidates targeting DUBs. Its hybrid business model emphasizes the generation of intellectual property while maintaining an internal pipeline of drug discovery programs aimed at optimizing compounds for critical therapeutic areas.

Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, that specializes in non-contact vital signs monitoring. Founded in 2012, it has developed the Oxecam software, which allows for the remote measurement of heart rate, respiratory rate, and blood oxygenation using digital video cameras. This innovative approach is particularly beneficial in medical settings, where it can enhance care for elderly and vulnerable individuals in environments where staff presence is limited. The system generates alerts for risky activities and provides objective data on patient vitals, enabling informed care planning. Oxehealth's technology combines proprietary algorithms that leverage deep learning, computer vision, and signal processing, making it suitable for various sectors, including healthcare, security, and retail. Its Digital Care Assistant supports clinicians and caregivers in mental health facilities, prisons, and home care, facilitating proactive interventions based on real-time data. Oxehealth is recognized for achieving the world’s first medical device certification for its software, demonstrating its commitment to enhancing patient care through innovative technology.

Iksuda Therapeutics is a biotechnology company focused on developing next-generation biotherapeutics, specifically antibody-drug conjugates designed to treat challenging cancers, including those resistant to current therapies.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Activiomics Ltd. is a biotechnology company specializing in biomarker technology and phosphoproteomics solutions aimed at enhancing biomarker discovery and drug candidate profiling. The company has developed a patented mass spectrometry-based technology that facilitates the global quantitative analysis of phosphorylation sites, which are critical mediators of cellular processes. This technology, known as TIQUAS (Targeted In-depth QUAntification of cell Signalling), allows for the quantification of thousands of phosphorylation events from tissue samples. By identifying and quantifying proteins and phosphoproteins that correlate with disease progression and drug administration, Activiomics aims to transform the development of diagnostics and therapeutic strategies.

Iksuda Therapeutics is a biotechnology company focused on developing next-generation biotherapeutics, specifically antibody-drug conjugates designed to treat challenging cancers, including those resistant to current therapies.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

TheraGenetics was spun out of King's College London in April 2006. Their technology is based upon pharmacogenetics; the study of genetic factors involved in influencing an individual's response to drug treatments. The strong foundation of TheraGenetics stems from the founding team's long commitment to pharmacogenetics that has situated us at the cutting edge of personalised medicine. Under the umbrella of the Institute of Psychiatry at King's College London, the founding team translated 15 years of research into the commercial world by developing the first pharmacogenetic test for response prediction in psychiatry. In 2005, this test which focuses on the schizophrenia treatment clozapine, was successfully licensed by King's College London to a major UK laboratory who have successfully brought the test to market in 2006. Based on this achievement and the overwhelming enthusiasm for personalised medicine solutions, King's College London, the academic founders and the London based venture firm IPGroup PLC launched TheraGenetics in April 2006. TheraGenetics unique knowledge and experience in CNS disorders extends from the bench to the bedside. The ultimate clinical utility has been a priority consideration at all stages of their test development; their clinical team knows what is required at the patient care interface and they develop tests accordingly. The TheraGenetic's team has a threshold of knowledge and experience spanning the whole test development process that is now allowing us to rapidly advance their work in the field of pharmacogenetic response prediction.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Cerogenix is a drug discovery and diagnostics.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.